ReviewSurgery today2019
Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues.
Review in Surgery today, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of pulmonary metastasectomy in patients suffering pancreatic ductal adenocarcinoma with lung metastases: a systematic review and meta-analysis.Frontiers in surgery · 2025Pooled it
- Dynamic transcriptional immune landscape in response to NK-cell therapy combined with gemcitabine plus S-1 in advanced pancreatic cancer: a phase 1b/2 trial.Signal transduction and targeted therapy · 2025Trial
- p38α Signaling Is Associated with Pancreatic Ductal Adenocarcinoma Progression and Represents a Potential Therapeutic Vulnerability.International journal of molecular sciences · 2026Article
- Article
- Successful conversion surgery for patients with pancreatic cancer, positive peritoneal cytology, and liver metastasis who were treated with chemotherapy involving nanoliposomal irinotecan with fluorouracil and folinic acid.Clinical journal of gastroenterology · 2025Article
- Article
- Carbon-ion irradiation together with autophagy inhibition and immune checkpoint inhibitors protect against pancreatic cancer development in mouse model.Journal of hepato-biliary-pancreatic sciences · 2025Article
- Enhancing pancreatic cancer treatment: the role of H101 oncolytic virus in irreversible electroporation.Frontiers in immunology · 2025Article
- Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma.Cancer research and treatment · 2024Article
- Conversion surgery for initially unresectable locally advanced pancreatic ductal adenocarcinoma after chemotherapy followed by carbon-ion radiotherapy: a case report.Journal of medical case reports · 2024Article
- Clinical benefits of pulmonary resection for lung metastases from pancreatic cancer.Langenbeck's archives of surgery · 2023Article
- Article
- New nomogram for predicting lymph node positivity in pancreatic head cancer.Frontiers in oncology · 2023Article
- Conversion surgery for undifferentiated carcinoma with osteoclast-like giant cells of the pancreas: a case report.Surgical case reports · 2022Article
- PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.Journal of Cancer · 2022Article
- The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer.Surgery today · 2021Article
- Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center.Journal of clinical medicine · 2021Article
- Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases.Surgery today · 2021Article
- Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer.Scientific reports · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the most lethal of all malignancies. One of the reasons for the dismal prognosis is that most diagnoses are made when the disease is either locally advanced or metastatic. Recent advances in chemotherapy and chemoradiotherapy (CRT) enable "conversion surgery" to be performed for selected patients with initially unresectable pancreatic cancer following favorable responses to preoperative treatment. Using FOLFIRINOX as preoperative treatment, the resection rate was reported as 6-44% of patients with locally advanced cancer and the prognosis of these patients was favorable. Even for metastasized cancer, recent reports show the effectiveness of conversion surgery, which has achieved 27-56 months of median overall survival. However, there are many unanswered questions about conversion surgery. The optimal regimen and duration of preoperative treatment remain unclear and there is still debate regarding the safety and effectiveness of vascular resection, which is often required for curative resection of locally advanced cancer. Accumulation of more data on conversion surgery is required to establish the safety and effectiveness of this treatment. In this review, we summarize the current status and unresolved issues about conversion surgery for initially unresectable pancreatic cancer.
Indexed as
Identifiers
30949842What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.